PMN vs ARVN vs RCUS vs CRL

For growth investors, Arvinas, Inc.

(ARVN) is the stronger pick with -0. 3% revenue growth year-over-year, versus -4. 3% for Arcus Biosciences, Inc. (RCUS). Analysts rate ProMIS Neurosciences, Inc. (PMN) a "Buy" — based on 2 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Arcus Biosciences, Inc.

(RCUS) delivered a total return of -3. 1%, compared to -96. 4% for ProMIS Neurosciences, Inc. (PMN). Over 10 years, the gap is even starker: CRL returned +122. 4% versus PMN's -91. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), ProMIS Neurosciences, Inc.

(PMN) is the lower-risk stock at 1. 11β versus Arcus Biosciences, Inc. 's 2. 00β — meaning RCUS is approximately 81% more volatile than PMN relative to the S&P 500. On balance sheet safety, Arvinas, Inc. (ARVN) carries a lower debt/equity ratio of 2% versus 95% for Charles River Laboratories International, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Arvinas, Inc.

(ARVN) is pulling ahead at -0. 3% versus -4. 3% for Arcus Biosciences, Inc. (RCUS). On earnings-per-share growth, the picture is similar: Arvinas, Inc. grew EPS 53. 8% year-over-year, compared to -1555. 0% for Charles River Laboratories International, Inc.. Over a 3-year CAGR, RCUS leads at 30. 2% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

ProMIS Neurosciences, Inc.

(PMN) is the more profitable company, earning 0. 0% net margin versus -142. 9% for Arcus Biosciences, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: CRL leads at 12. 6% versus -156. 3% for RCUS. At the gross margin level — before operating expenses — ARVN leads at 98. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for ARVN: 94.

6% to $14. 75.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, ProMIS Neurosciences, Inc.

(PMN) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 11)). Arcus Biosciences, Inc. (RCUS) carries a higher beta of 2. 00 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (PMN: -91. 4%, RCUS: +40. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.